The Chinese Medicine Research Group, RMIT University, Bundoora West Campus, Victoria 3083, Australia.
Phytother Res. 2009 Sep;23(9):1270-5. doi: 10.1002/ptr.2608.
RCM-102 is a Chinese herbal medicine formulation derived from a formula which was shown to be effective in treating seasonal allergic rhinitis (SAR) in a randomized placebo-controlled trial. The aim of this study was to investigate the in vitro effect of RCM-102 on the formation of inflammatory mediators, histamine, prostaglandin and nitric oxide, which are known to be involved in the pathophysiology of SAR. The effect of RCM-102 on histamine release was tested in compound 48/80-stimulated rat peritoneal mast cells. The effects of RCM-102 on the release of NO and prostaglandins (PGE(2)) and the expression of inducible NO synthase (iNOS) and COX-2 were studied in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells. In rat peritoneal mast cells, RCM-102 significantly reduced the compound 48/80-induced histamine release. It also significantly reduced NO and PGE(2) production as well as the expression of COX-2 and iNOS in RAW 264.7 cells. These findings indicate that RCM-102 inhibits the formation of several allergic/inflammatory mediators and thus may be used for treating related conditions such as SAR. The actions of RCM-102 are likely to be contributed by the synergistic actions of individual herbal ingredients.
RCM-102 是一种中药配方,源自一种在随机安慰剂对照试验中被证明对治疗季节性过敏性鼻炎(SAR)有效的配方。本研究旨在研究 RCM-102 对炎症介质、组胺、前列腺素和一氧化氮形成的体外影响,这些介质已知参与 SAR 的病理生理学。在复合 48/80 刺激的大鼠腹腔肥大细胞中测试了 RCM-102 对组胺释放的影响。在脂多糖(LPS)刺激的 RAW 264.7 细胞中研究了 RCM-102 对 NO 和前列腺素(PGE2)释放以及诱导型一氧化氮合酶(iNOS)和 COX-2 表达的影响。在大鼠腹腔肥大细胞中,RCM-102 显著减少了复合 48/80 诱导的组胺释放。它还显著减少了 RAW 264.7 细胞中 NO 和 PGE2 的产生以及 COX-2 和 iNOS 的表达。这些发现表明,RCM-102 抑制了几种过敏/炎症介质的形成,因此可用于治疗相关疾病,如 SAR。RCM-102 的作用可能是由单个草药成分的协同作用贡献的。